Moderna reported a surprise Q3 2026 profit of $0.38 per share versus an expected loss, with revenue rising to $1.31 billion due to strong international COVID-19 vaccine demand. The company raised its 2026 revenue growth forecast to 15-25% and expects lower R&D spending. Moderna's stock rose 5% amid optimism about its cancer vaccine pipeline and new product approvals, though some gains faded after an initial surge. Investors remain cautious about the durability of overseas vaccine demand and await updates on key drug filings and litigation outcomes.
As of Nov 06, 2026 23:21 WIB, Moderna's stock on Pluang is up 7.89% at USD 260.51, reflecting strong investor interest following its positive earnings report. Meanwhile, Pfizer shares have dipped 0.61% to USD 29.27, and BioNTech is slightly higher by 1.09% at USD 86.80. Notably, Moderna's market cap stands at $96.40 billion, highlighting its significant presence in the health sector.
Moderna's stock price has surged 700% this year amid excitement over its experimental cancer vaccine. However, the company's recent earnings reveal that its revenue growth remains largely driven by strong international demand for its Covid vaccines. ...
Moderna increased its revenue outlook for 2026, now expecting growth between 15% and 25%, up from a previous forecast of 10%. The company, known for its mRNA COVID-19 vaccine Spikevax, cited strong sales as the reason for the optimistic update. This ...
Moderna exceeded third-quarter revenue and earnings expectations, reporting $1.31 billion in revenue and 38 cents earnings per share, compared to analyst estimates of $885.1 million and a loss of $1.25 per share. The company raised its 2026 revenue g...
On November 6, Moderna, Humana, and Elanco will release earnings reports that could impact their stock rallies. Humana's Medicare Advantage update is crucial for retirees, with a focus on medical costs and membership trends. Elanco faces supply chall...
Moderna's stock is rated Strong Sell at $220.83, with a valuation around $60 per share, implying a 73% downside. This is despite promising Phase 3 melanoma trial results showing a 42% reduction in relapse or death when using intismeran with Keytruda....
